News
Sensorion Announces That an Extraordinary General Meeting Will Be Held Behind Closed Doors on March 24, 2021
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
BIOCORP unterzeichnet zwei neue Vereinbarungen zur Nutzung von Mallya-Technologie
BIOCORP (FR0012788065 - ALCOR / PEA/KMU-qualifiziert) (Paris:ALCOR), ein französisches Unternehmen mit Spezialisierung auf die Gestaltung, Entwicklung und Herstellung von innovativen
Sensorion : A Chardan Top Pick for 2021
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
BIOCORP Signs Two New Partnerships With Mallya Technology
Regulatory News:
BIOCORP (FR0012788065 - ALCOR / Eligible PEA PME) (Paris:ALCOR), a French company specialized in the design, development and manufacturing of innovative medical devices, today
VALBIOTIS autorisiert den Start von HEART, der multizentrischen klinischen Phase-II-Studie zu TOTUM-070 zur Senkung des LDL-Cholesterinspiegels
VALBIOTIS (FR0013254851 – ALVAL / qualifiziert für PEA/SME, französischer Aktiensparplan zur Finanzierung von KMUs) (Paris:ALVAL), ein französisches Forschungs- und Entwicklungsunternehmen mit
Sensorion Announces Third Gene Therapy Collaboration With Institut Pasteur Targeting Important Pediatric and Adult Deafness Segments
Regulatory News:
Sensorion (Paris:ALSEN)(FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
VALBIOTIS Authorized to Launch HEART, the Phase II Multi-center Clinical Study With TOTUM-070, for the Reduction of Blood LDL-cholesterol Levels
VALBIOTIS (FR0013254851 – ALVAL / eligible for the PEA/SME, French equity savings plan for the financing of SMEs) (Paris:ALVAL), a Research & Development company committed to scientific innovation
GenSight Biologics Announces Publication of Results from LUMEVOQ® Phase I/IIa Clinical Trial REVEAL in BioDrugs
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non‑Human Primates
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
GenSight Biologics Reports Cash Position as of December 31, 2020 and Provides Operational Update
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
Sensorion Announces Preclinical Data Demonstrating SENS-401’s Potential to Preserve Residual Hearing After Cochlear Implantation
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
THERANEXUS PRESENTS AN UPDATE ON THE PROGRESS OF ITS MAIN PROGRAMS AND ANNOUNCES ITS CASH POSITION AS OF 31 DECEMBER 2020
IMPLEMENTATION OF A NEW EQUITY LINE
Lyon, 18 January 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug
GenSight Biologics Announces its 2021 Financial Calendar
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
GenSight Biologics Announces Publication of Results from LUMEVOQ® RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology®
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
VALBIOTIS kündigt Teilnahme an der 39. jährlichen J.P. Morgan Healthcare Conference und der H.C. Wainwright BioConnect vom 11. bis 14. Januar 2021 im virtuellen Format an
VALBIOTIS (FR0013254851 – ALVAL / qualifiziert für PEA/SME) (Paris:ALVAL), ein französisches Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung
VALBIOTIS Announces Its Participation in the 39th J.P. Morgan Healthcare Annual Conference as well as in H.C. Wainwright BioConnect from January 11-14, 2021, in Virtual Format
Regulatory News:
VALBIOTIS (FR0013254851 – ALVAL / eligible for the PEA/SME) (Paris:ALVAL), a French Research & Development company committed to scientific innovation for preventing and combating
EOS Imaging Reports Full-Year 2020 Revenue up +19% Year-on-year
Regulatory News:
EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible) (Paris:EOSI), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and
Sensorion Announces Initiation of Coverage by Investment Banks Jefferies and Kempen With a “Buy” Recommendation
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Sensorion Provides an Update on Plans and Progress in the Development of SENS-401 for the Prevention of Hearing Loss
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2021
Lyon, December 28, 2020 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction
EOS imaging Announces Its Financial Agenda For 2021
Regulatory News:
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and
THERANEXUS, LYON NEUROSCIENCE RESEARCH CENTER AND CERMEP ANNOUNCE THE CREATION AND FUNDING OF NEW JOINT PUBLIC/PRIVATE LABORATORY "NEUROIMAGING FOR DRUG DISCOVERY" (NI2D)
The laboratory obtained funding of €350,000 from the French National Research Agency (ANR).
Lyon, 18 December 2020 – Theranexus, a biopharmaceutical company innovating in the treatment of
Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the “Imaging and Robotics in Surgery (IRiS) Alliance”
Regulatory News:
Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’) a biopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) and Mauna
Sonova Invests €5 Million in Sensorion as the Companies Plan a Collaboration in Hearing Loss
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT) (the "Company" or "GenSight"), a biopharma company focused on developing and